Horizon Therapeutics plc: Sustained Patient Response to KRYS

-- Month 12 results from MIRROR randomized controlled trial to be featured on Nov. 13, 11:45 a.m. EST during plenary session at the American College of Rheumatology Convergence 2022 -- -- Imaging

Related Keywords

Alaska , United States , Ireland , Amanda Phraner , Clin Rheumatol , Tina Ventura , Johnk Botson , Ada Kumar , Ray Gordon , Erin Linnihan , Instagram , Energy Computed Tomography , Product Communications , Patients With Uncontrolled Gout Co , Linkedin , American College Of Rheumatology Convergence , Twitter , Nasdaq , Exchange Commission , Gout Patients Using Dual Energy Computed Tomography , Alaska Rheumatology Alliance , Facebook , American College , Rheumatology Convergence , Orthopedic Physicians , Safety Study , Increase Response Rates , Receiving Pegloticase , Monosodium Urate Crystal Deposit Volume During , Patients Treated , Pegloticase Plus Methotrexate Co Therapy , Serial Dual Energy Computed Tomography , Mount Sinai Hospital , Urate Deposition , Positron Emission Tomography Pre , Post Pegloticase , Uncontrolled Gout Receiving , Heart Failure , Full Prescribing Information , Combination With Methotrexate , Patients With Uncontrolled Gout , Open Label Study , Pegloticase Response , Proof Of Concept Case , Randomized Placebo Controlled Study , Primary Efficacy , Accepted Author , Vice President , Chief Investor Relations Officer , Investor Relations , Media Contact , Horizon , Herapeutics , Sustained , Patient , Response , Krystexxa , Egloticase , Injection , Ethotrexate , Ompared , Alone , Hown , Through , Month , Mirror , Randomized , Ontrolled , Trial ,